Peptic Ulcer Drugs Market by Product Type (H2 receptor Antagonists, Proton Pump Inhibitors (PPIs), Antacids, Ulcer Protective Drugs, Potassium-Competitive Acid Blockers (P-CAB), Antibiotics, Others), By Formulation (Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections), By Application (Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Peptic Ulcer Drugs Market size was valued at USD 4.1  billion in 2021, growing at a significant CAGR of 2.1% from 2022-28. Peptic ulcer drugs market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The report on global gives historical, current, and future market sizes (US$ Mn) on the basis of product type, formulation, application, distribution channel, and regions. This report studies global dynamics elaborately to identify the current market trends and drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global report includes competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global Peptic ulcer drugs market to better equip clients with possible investment opportunities across the regions and market unmet needs (Product Opportunities). Key stakeholders of the global report include suppliers, manufacturers, marketers, policy makers, and agronomists engaged in global activities. low profile additives market is consolidating as large players complementing each other’s businesses by means of collaborations, agreements and acquisitions. Peptic ulcers are used in the treatment of certain types of gastrointestinal disorders that include gastric ulcers, gastritis, and duodenal ulcers or gastroesophagal reflux disease (GERD). These drugs minimize the amount of acid produced by the stomach. The most common symptoms associated with peptic ulcer include abdominal pain, vomiting, belching, poor appetite, and weight loss. Peptic ulcers can be treated by using various drugs such as proton pumps inhibitors (PPIs), H2 receptor antagonists, antacids, and antibiotics among others In February 2018, Strides Shasun decided to launch the Ranitidine 150 mg over the counter drug in U.S. for the treatment of peptic ulcers

Global Peptic Ulcer Drugs Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Peptic Ulcer Drugs Market Drivers and Restraints

Increase in the global geriatric population, rise in prevalence of peptic ulcers due to change in food habits, and increase in the consumption of tobacco and alcohol are key factors surge the global peptic ulcer drugs market. Moreover, rise in R&D for the development of newer drugs, rise in number of drug induced peptic ulcer cases, availability of cost-effective drugs, and rise in awareness about the peptic ulcers among the people are anticipated to surge the global peptic ulcer drugs market over the forecast years. However, adverse effects associated with the drugs, patent expiries of block buster drugs, poor pipeline products, and changes in pricing policies are hamper the growth of global peptic ulcer drugs market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis

Global Peptic Ulcer Drugs Market Segmentation

Product Type
  • H2 receptor Antagonists
  • Proton Pump Inhibitors (PPIs)
  • Antacids
  • Ulcer Protective Drugs
  • Potassium-Competitive Acid Blockers (P-CAB)
  • Antibiotics
  • Others
  • Oral tablets
  • Effervescent Tablets
  • Effervescent Granules
  • Syrups
  • Injections
  • Gastroesophagal Reflux Disease (GERD)
  • Gastritis
  • Duodenal Ulcers
  • Gastric Ulcers
  • Others
  • North America,
  • Latin America,
  • Europe,
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The peptic ulcer drugs market is projected to expand at a CAGR of 2.1% during the forecast period.  

Pfizer, Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Abbott Laboratories (U.S.), Takeda Pharmaceuticals Co. Ltd (Japan), GlaxoSmithKline plc (UK)

North America is the fastest-growing region for the peptic ulcer drugs market


  • Pfizer, Inc. (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Abbott Laboratories (U.S.)
  • Takeda Pharmaceuticals Co. Ltd (Japan)
  • GlaxoSmithKline plc (UK)
  • Yuhan Co. Ltd. (South Korea)
  • AstraZeneca plc (UK)
  • Eisai Co. Ltd. (U.S.)
  • Helicure AB (Sweden)
  • Cadila Healthcare (India)